Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Gsk3β regulates the resolution of liver ischemia/reperfusion injury via MerTK
Hanwen Zhang, … , Xuehao Wang, Yuan Zhai
Hanwen Zhang, … , Xuehao Wang, Yuan Zhai
Published November 24, 2022
Citation Information: JCI Insight. 2023;8(1):e151819. https://doi.org/10.1172/jci.insight.151819.
View: Text | PDF
Research Article Hepatology Immunology

Gsk3β regulates the resolution of liver ischemia/reperfusion injury via MerTK

  • Text
  • PDF
Abstract

Although glycogen synthase kinase β (Gsk3β) has been shown to regulate tissue inflammation, whether and how it regulates inflammation resolution versus inflammation activation is unclear. In a murine liver, partial warm ischemia/reperfusion injury (IRI) model, we found that Gsk3β inhibitory phosphorylation increased at both the early-activation and late-resolution stages of the disease. Myeloid Gsk3β deficiency not only alleviated liver injuries, it also facilitated the restoration of liver homeostasis. Depletion of Kupffer cells prior to the onset of liver ischemia diminished the differences between the WT and Gsk3β-KO mice in the activation of liver IRI. However, the resolution of liver IRI remained accelerated in Gsk3β-KO mice. In CD11b-DTR mice, Gsk3β-deficient BM-derived macrophages (BMMs) facilitated the resolution of liver IRI as compared with WT cells. Furthermore, Gsk3β deficiency promoted the reparative phenotype differentiation in vivo in liver-infiltrating macrophages and in vitro in BMMs. Gsk3 pharmacological inhibition promoted the resolution of liver IRI in WT, but not myeloid MerTK-deficient, mice. Thus, Gsk3β regulates liver IRI at both activation and resolution stages of the disease. Gsk3 inactivation enhances the proresolving function of liver-infiltrating macrophages in an MerTK-dependent manner.

Authors

Hanwen Zhang, Ming Ni, Han Wang, Jing Zhang, Dan Jin, Ronald W. Busuttil, Jerzy W. Kupiec-Weglinski, Wei Li, Xuehao Wang, Yuan Zhai

×

Figure 7

MerTK is critical for the proresolving therapeutic effect of pharmacological Gsk3 inhibition.

Options: View larger image (or click on image) Download as PowerPoint
MerTK is critical for the proresolving therapeutic effect of pharmacolog...
WT and myeloid MerTK-KO mice were treated with CLs 48 hours prior to the onset of liver ischemia. Vehicle control (Ctl) and SB216763 were administered at 24 hours and on days 3 and 5 after reperfusion, as described Methods. IR livers were harvested on day 7 after reperfusion. (A) Liver gross appearance and histological images of different experiment groups. (B) Average Suzuki scores of IR livers of different experimental groups at day 7 after reperfusion. (C) Average ratios of target gene to HPRT in IR livers of different experimental groups at day 7 after reperfusion. Liver gene expression was determined by quantitative reverse-transcription PCR. Data represent mean ± SEM. Representative results from 4–6 livers/group. *P < 0.05 (Student’s t test).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts